Scholarlink

Background <p>Treatment outcomes for high-risk B-ALL remain suboptimal. Blinatumomab, a CD19/CD3 bispecific T-cell engager, has shown efficacy in trials, but real-world data in Chinese high-risk patients are limited.</p> Methods <p>This single-center retrospective study analyzed 29 high-risk B-ALL patients treated with blinatumomab (7–28 days/cycle). We assessed short-term efficacy (MRD negativity rate), safety, and the impact of genetic factors and treatment duration.</p> Results <p>The overall MRD negativity rate after one cycle of blinatumomab was 82.8% (24/29). All patients with the Ph-like subtype (3/3, 100%) and 71.4% (10/14) of Ph+ patients achieved MRD negativity. However, clinical outcomes were inferior in patients harboring specific genetic alterations: 50% (2/4) of patients with the <i>BCR::ABL1</i> T315I mutation experienced early relapse, and only one of two patients with <i>E2A::PBX1</i> rearrangement achieved transient MRD negativity. The median event-free survival (EFS) was 9.6 months (95% CI: 6–16.75). Grade ≥ 3 hematologic toxicity occurred in 48.3% (14/29) of the patient cohort.</p> Conclusion <p>Blinatumomab achieved high short-term MRD response rates in high-risk B-ALL. Inferior outcomes appeared to be associated with the presence of <i>BCR::ABL1</i> T315I mutations and <i>E2A::PBX1</i> rearrangements.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A single-center retrospective study of short-term efficacy and safety of blinatumomab in the treatment of high-risk acute lymphoblastic leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Yixuan Ma,
  • Luyang Chang,
  • Lin Wang,
  • Lin Chen,
  • Xudong Wei,
  • Ruihua Mi

摘要

Background

Treatment outcomes for high-risk B-ALL remain suboptimal. Blinatumomab, a CD19/CD3 bispecific T-cell engager, has shown efficacy in trials, but real-world data in Chinese high-risk patients are limited.

Methods

This single-center retrospective study analyzed 29 high-risk B-ALL patients treated with blinatumomab (7–28 days/cycle). We assessed short-term efficacy (MRD negativity rate), safety, and the impact of genetic factors and treatment duration.

Results

The overall MRD negativity rate after one cycle of blinatumomab was 82.8% (24/29). All patients with the Ph-like subtype (3/3, 100%) and 71.4% (10/14) of Ph+ patients achieved MRD negativity. However, clinical outcomes were inferior in patients harboring specific genetic alterations: 50% (2/4) of patients with the BCR::ABL1 T315I mutation experienced early relapse, and only one of two patients with E2A::PBX1 rearrangement achieved transient MRD negativity. The median event-free survival (EFS) was 9.6 months (95% CI: 6–16.75). Grade ≥ 3 hematologic toxicity occurred in 48.3% (14/29) of the patient cohort.

Conclusion

Blinatumomab achieved high short-term MRD response rates in high-risk B-ALL. Inferior outcomes appeared to be associated with the presence of BCR::ABL1 T315I mutations and E2A::PBX1 rearrangements.